Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Commercial plans.

When does this change take effect?

This change is effective Apr 2, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.02.18, Elranatamab-bcmm (Elrexfio™)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Apr 2, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Insurance policy for Elranatamab-bcmm (Elrexfio™), a pharmacy medication, has been updated and reissued. This is a very recent pharmacy policy change that may affect coverage or billing requirements for this specialized medication.

Action Required

Action needed

By April 2, 2025: Billing team should review the complete policy details at the provided URL to understand any changes to coverage, prior authorization, or billing requirements for Elranatamab-bcmm (Elrexfio™). Update billing protocols and staff training as needed based on the full policy content.

Related policy hubs

Independence Blue Cross policies Oncology Hematology